Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-25-001347
Filing Date
2025-05-15
Accepted
2025-05-15 17:10:21
Documents
51
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q bcli-20250331x10q.htm   iXBRL 10-Q 930378
2 EX-31.1 bcli-20250331xex31d1.htm EX-31.1 8763
3 EX-31.2 bcli-20250331xex31d2.htm EX-31.2 9382
4 EX-32.1 bcli-20250331xex32d1.htm EX-32.1 5993
5 EX-32.2 bcli-20250331xex32d2.htm EX-32.2 6024
  Complete submission text file 0001410578-25-001347.txt   3656713

Data Files

Seq Description Document Type Size
6 EX-101.SCH bcli-20250331.xsd EX-101.SCH 28933
7 EX-101.CAL bcli-20250331_cal.xml EX-101.CAL 27512
8 EX-101.DEF bcli-20250331_def.xml EX-101.DEF 113646
9 EX-101.LAB bcli-20250331_lab.xml EX-101.LAB 226455
10 EX-101.PRE bcli-20250331_pre.xml EX-101.PRE 195977
54 EXTRACTED XBRL INSTANCE DOCUMENT bcli-20250331x10q_htm.xml XML 404405
Mailing Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019
Business Address 1325 AVENUE OF AMERICAS 28TH FLOOR NEW YORK NY 10019 201-488-0460
BRAINSTORM CELL THERAPEUTICS INC. (Filer) CIK: 0001137883 (see all company filings)

EIN.: 207273918 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36641 | Film No.: 25955292
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)